{"filings":[{"id":95395,"accession_number":"0001193125-26-213269","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.","Net loss $13.6M vs $15.8M in Q1 2025; R&D expense $9.7M vs $12.1M.","KOMODO-1 first-in-human trial of BBI-940 enrolling patients with ER+/HER2- and TNBC-LAR breast cancer.","AACR 2026 data showed tumor regression from BBI-940 in ecDNA+ TNBC-LAR and ER+ breast cancer models.","G&A expense $4.7M vs $5.2M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95394,"accession_number":"0001193125-26-153076","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.02","2.03"],"status":"ready","headline":"Boundless Bio terminates 80,168 sq ft San Diego lease; pays $10M, forfeits $0.5M deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease originally set to expire Oct 2034; terminated effective May 31, 2026.","Company pays $10.0M lease modification payment plus $0.5M security deposit to landlord ARE-10933 North Torrey Pines.","Condition precedent satisfied: Landlord has leased premises to a new tenant.","Lease termination affects Company's lab and office space at 10955 Alexandria Way, San Diego."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108456,"accession_number":"0001193125-26-097535","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Boundless Bio Q4 net loss $12.9M; cash $107.6M; ceases POTENTIATE enrollment; BBI-940 trial enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.","Cash, cash equivalents, and short-term investments total $107.6M; expected runway into H2 2028 through initial proof-of-concept readout for KOMODO-1.","Ceased enrollment in Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) due to market considerations and prioritization of BBI-940 program.","KOMODO-1 first-in-human trial of BBI-940 (oral Kinesin degrader) open for enrollment in ER+/HER2- and TNBC-LAR breast cancer.","Director Christine Brennan resigned effective March 3, 2026 due to new role at Johnson & Johnson Development Corp., no disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124889,"accession_number":"0001193125-25-265707","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).","Cash, cash equivalents and short-term investments of $117.6M as of Sept 30, 2025.","Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial.","IND submission for BBI-940 on track; Phase 1 trial expected in H1 2026.","Cash runway into first half of 2028 through proof-of-concept clinical readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141595,"accession_number":"0000950170-25-102386","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q2 net loss $15.7M; cash $127.1M funds operations into H1 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.7M in Q2 2025 versus $17.0M in Q2 2024; R&D expenses fell to $12.2M from $14.7M.","Cash and investments $127.1M at June 30, 2025, supporting operations and proof-of-concept readouts into first half 2028.","BBI-355/BBI-825 combination arm of POTENTIATE trial open for enrollment; initial proof-of-concept data expected within cash runway.","BBI-940 (novel kinesin program) IND submission on track for first half 2026; clinical data anticipated within existing cash timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159449,"accession_number":"0000950170-25-089002","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Boundless Bio annual meeting elects two directors, ratifies KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christine Brennan, Ph.D. elected as Class I director with 9,252,440 votes for and 5,046,258 withheld; 3,540,518 broker non-votes.","Nancy Whiting, Pharm.D. elected as Class I director with 9,758,214 votes for and 4,540,484 withheld; 3,540,518 broker non-votes.","Ratification of KPMG LLP as independent auditor for FY2025: 17,791,309 for, 47,807 against, 100 abstain.","Meeting held on June 23, 2025; both proposals were standard agenda items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159448,"accession_number":"0000950170-25-076911","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.","Discontinues current POTENTIATE trial arms for BBI-355 due to narrow therapeutic index and poor tolerability.","Plans to develop BBI-355/BBI-825 combination; initial clinical data expected within extended cash runway.","Selects BBI-940 as Kinesin program candidate; IND submission expected first half 2026.","Cash, equivalents & investments $138.3M as of March 31, 2025; operating runway extended into first half 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159447,"accession_number":"0000950170-25-067495","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.","Net loss of $15.8M for Q1 2025 versus $15.4M in Q1 2024; R&D expenses $12.1M ($13.1M Q1 2024), G&A $5.2M ($3.8M).","BBI-355 Phase 1/2 POTENTIATE trial enrollment ongoing; preliminary clinical proof-of-concept data expected second half 2025.","Novel Kinesin program: development candidate nomination expected mid-2025, IND filing planned for first half 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159446,"accession_number":"0001193125-25-070496","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Boundless Bio enters $14.5M ATM equity distribution agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $14.5M of common stock via at-the-market offerings through Jefferies LLC.","Shares sold at prevailing market prices; Jefferies receives up to 3.0% commission on gross proceeds.","No minimum sale obligation; either party may terminate the agreement on prior written notice.","Issuance is subject to SEC effectiveness of Form S-3 registration statement filed April 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177840,"accession_number":"0000950170-25-045722","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.","Cash and investments $152.1M as of Dec 31, 2024; projected operating runway into 2027.","BBI-355 Phase 1/2 POTENTIATE trial ongoing; initial proof-of-concept safety/activity data due H2 2025.","Novel Kinesin program: development candidate nomination targeted for mid-2025, IND submission H1 2026.","Appointed Dr. Robert Doebele as Chief Medical Officer in February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194546,"accession_number":"0000950170-24-135768","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.","BBI-355 Phase 1/2 POTENTIATE trial on track for initial clinical data readout in H2 2025; enrollment ongoing.","Third ecDTx program targeting a kinesin for ecDNA segregation; development candidate nomination expected mid-2025, IND in H1 2026.","CMO Klaus Wagner and CBO Neil Abdollahian departing; James Freddo named Interim CMO while search for permanent CMO begins.","Cash, equivalents, and short-term investments sufficient to fund operations into 2027 through anticipated milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194545,"accession_number":"0000950170-24-123274","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.","Cash, cash equivalents, and short-term investments total $167.1M as of Sept 30, 2024.","Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP trials; initial proof-of-concept data expected H2 2025.","Analytical validation for proprietary ecDNA diagnostic ECHO presented at ESMO September 2024.","G&A expenses $4.6M vs $3.3M year-over-year; general operating cash runway into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194544,"accession_number":"0000950170-24-114466","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Boundless Bio CFO Jami Rubin steps down; David Hinkle named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jami Rubin resigned as CFO and Treasurer effective October 11, 2024.","David Hinkle, SVP Finance & Controller, appointed as Treasurer, principal financial officer and principal accounting officer.","Rubin eligible for severance per company's Severance Plan as a Tier 2 employee.","Hinkle joined Boundless Bio in 2021; prior roles at Crinetics Pharmaceuticals, Ignyta, Receptos."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210877,"accession_number":"0000950170-24-099185","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Boundless Bio reprices options for execs to $3.56; CEO Hornby holds 1.15M repriced options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise price reduced to $3.56 (Aug 19, 2024 close) for options originally priced at or above $3.71.","Repriced options may only be exercised at the lower price if held through the Premium End Date (Aug 19, 2026, or earlier change in control or qualifying termination).","CEO Zachary D. Hornby: 1,147,242 options repriced (original exercise range $4.10–$16.00).","CMO Klaus Wagner: 316,893 options; CSO Chris Hassig: 292,821 options repriced.","Repricing intended to retain key employees without incurring dilution from additional equity grants or cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210876,"accession_number":"0000950170-24-095481","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.","Cash, equivalents, and short-term investments $179.3M as of June 30, 2024.","BBI-355 combo cohort enrollment slower than expected; initial proof-of-concept data now H2 2025.","BBI-825 first patient dosed in April 2024; initial data also expected H2 2025.","Workforce reduced and operations streamlined to extend runway into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229288,"accession_number":"0000950170-24-058186","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.","Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.","BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.","First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229287,"accession_number":"0001193125-24-084736","cik":1782303,"company_name":"Boundless Bio, Inc.","ticker":"BOLD","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Boundless Bio completes IPO of 6.25M shares at $16.00, raising $100M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed April 2, 2024; 6,250,000 shares sold at $16.00 per share.","Gross proceeds of $100.0 million before underwriting discounts and expenses.","Amended charter increases authorized common to 700M shares, authorizes 70M preferred shares.","Board classified into three classes with staggered three-year terms; removal only for cause with 2/3 vote.","Stockholder action by written consent eliminated; exclusive forum provisions adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32909923.442176875,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}